tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Karyopharm Therapeutics Inc

KPTI
Add to Watchlist
1.610USD
-0.010-0.62%
Close 09-11 16:00（ET）
36.40MMarket Cap
LossP/E TTM
After-hours 17:18 (ET)1.620USD+0.020+1.25%

Karyopharm Therapeutics Inc

1.610
-0.010-0.62%
Overview
News&Analysis
Financials
Stock Score
Technical
Forecast
Ownership
Dividends
Profile
Discussions
Financial SummaryIncome StatementBalance SheetCash Flow StatementEarningsCompany ValuationRisk Assessment

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial SummaryIncome StatementBalance SheetCash Flow StatementEarningsCompany ValuationRisk Assessment

KPTI Financials

See Karyopharm Therapeutics Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Key Financial Ratios

Market Cap
36.40M
Dividend TTM
0.00
P/E TTM
-0.10
EPS TTM
-16.17
Revenue
146.07M
Net Profit
-76.42M
ROE
0.00%
ROA
-150.48%

Karyopharm Therapeutics Inc Earnings Date

Latest Release
Aug 13, 2026
EPS / Forecast
-2.32/-1.28
Revenue / Forecast
33.43M/32.19M

Financial Statement Highlights

Quarterly
Quarterly+Annual
Quarterly
Annual
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
Financial Indicators
EPS
46.41%-2.32
63.28%-1.02
-55.02%-5.68
0.70%-3.82
-246.56%-4.32
42.94%-2.77
32.93%-3.67
14.94%-3.85
168.80%2.95
-7.61%-4.85
14.79%-5.47
---4.52
---4.29
---4.51
---6.42
----
----
----
----
----
Revenue
-11.86%33.43M
16.83%35.07M
11.58%34.08M
13.57%44.04M
-11.35%37.93M
-9.39%30.02M
-9.50%30.54M
7.70%38.78M
13.86%42.79M
-14.40%33.13M
0.50%33.75M
-0.38%36.01M
-5.29%37.58M
-18.82%38.70M
-73.41%33.58M
-4.10%36.15M
75.56%39.68M
104.94%47.67M
259.74%126.27M
76.67%37.69M
Net Profit
-79.92%-67.02M
4.56%-22.39M
-232.03%-102.20M
-3.29%-33.13M
-256.57%-37.25M
37.20%-23.46M
26.43%-30.78M
7.05%-32.07M
172.91%23.79M
-9.48%-37.36M
-8.65%-41.84M
5.00%-34.51M
33.49%-32.63M
17.57%-34.13M
-199.45%-38.51M
29.89%-36.32M
8.44%-49.06M
27.89%-41.40M
189.17%38.72M
3.15%-51.81M
Net Margin
-104.12%-200.48%
18.31%-63.86%
-197.57%-299.89%
9.05%-75.21%
-276.62%-98.22%
30.69%-78.17%
18.71%-100.78%
13.70%-82.70%
164.04%55.61%
-27.90%-112.79%
-8.11%-123.97%
---95.83%
---86.83%
---88.19%
---114.67%
----
----
----
----
----
Gross Margin
-0.49%96.75%
0.52%96.16%
0.00%95.65%
-1.50%95.20%
0.68%97.23%
1.52%95.67%
0.05%95.64%
-0.84%96.65%
-0.25%96.58%
-2.36%94.23%
1.23%95.60%
--97.47%
--96.82%
--96.51%
--94.44%
----
----
----
----
----
Debt to assets ratio
18.39%289.51%
14.07%225.79%
73.95%276.00%
96.08%273.29%
97.74%244.55%
33.30%197.94%
25.74%158.66%
24.11%139.38%
21.48%123.67%
59.65%148.49%
49.25%126.19%
--112.31%
--101.81%
--93.01%
--84.55%
----
----
----
----
----
Income Statement
Revenue
-11.86%33.43M
16.83%35.07M
11.58%34.08M
13.57%44.04M
-11.35%37.93M
-9.39%30.02M
-9.50%30.54M
7.70%38.78M
13.86%42.79M
-14.40%33.13M
0.50%33.75M
-0.38%36.01M
-5.29%37.58M
-18.82%38.70M
-73.41%33.58M
-4.10%36.15M
75.56%39.68M
104.94%47.67M
259.74%126.27M
76.67%37.69M
Operating profit
7.63%-22.53M
19.53%-26.76M
42.96%-17.84M
42.09%-15.22M
13.28%-24.39M
1.49%-33.26M
17.26%-31.28M
15.92%-26.28M
4.91%-28.12M
-9.26%-33.76M
-11.63%-37.81M
-1.37%-31.26M
31.08%-29.57M
10.66%-30.90M
-172.12%-33.87M
29.61%-30.84M
12.52%-42.91M
33.96%-34.59M
226.70%46.96M
7.00%-43.81M
Net Profit
-79.92%-67.02M
4.56%-22.39M
-232.03%-102.20M
-3.29%-33.13M
-256.57%-37.25M
37.20%-23.46M
26.43%-30.78M
7.05%-32.07M
172.91%23.79M
-9.48%-37.36M
-8.65%-41.84M
5.00%-34.51M
33.49%-32.63M
17.57%-34.13M
-199.45%-38.51M
29.89%-36.32M
8.44%-49.06M
27.89%-41.40M
189.17%38.72M
3.15%-51.81M
Balance Sheet
Current assets
8.69%106.38M
5.07%126.33M
-34.09%103.15M
-51.42%89.75M
-53.07%97.87M
-39.39%120.24M
-33.10%156.49M
-29.81%184.75M
-28.43%208.54M
-37.73%198.37M
-33.20%233.92M
18.21%263.22M
20.18%291.38M
15.19%318.54M
27.05%350.16M
-7.82%222.68M
-11.35%242.45M
8.23%276.53M
-0.33%275.61M
-15.37%241.58M
Total current liabilities
35.29%134.23M
29.80%117.30M
-0.22%92.06M
41.73%87.16M
72.19%99.22M
38.31%90.37M
32.79%92.26M
-0.94%61.49M
-2.22%57.62M
6.15%65.34M
5.42%69.48M
0.51%62.08M
-5.78%58.93M
-7.21%61.55M
-10.59%65.91M
-10.32%61.76M
7.60%62.54M
6.98%66.34M
22.45%73.72M
30.85%68.87M
Total assets
6.14%111.32M
2.90%131.42M
-34.06%108.42M
-49.21%96.23M
-50.99%104.88M
-37.54%127.71M
-31.62%164.42M
-29.81%189.48M
-28.15%213.98M
-37.24%204.46M
-32.87%240.44M
16.75%269.96M
16.12%297.83M
10.80%325.80M
17.32%358.17M
-9.00%231.24M
-10.50%256.48M
6.96%294.03M
-2.47%305.31M
-24.73%254.09M
Total liabilities
28.41%441.49M
19.03%397.06M
14.53%401.34M
4.69%365.49M
-0.67%343.81M
-10.66%333.60M
-6.96%350.44M
-5.73%349.12M
-6.22%346.12M
0.66%373.41M
0.48%376.64M
-0.31%370.36M
-1.00%369.08M
-1.63%370.97M
-2.64%374.83M
-2.25%371.52M
0.84%372.82M
19.89%377.11M
46.66%384.98M
49.74%380.07M
Total equity
-38.19%-330.17M
-29.03%-265.65M
-57.47%-292.93M
-68.66%-269.26M
-80.81%-238.93M
-21.86%-205.88M
-36.57%-186.02M
-59.02%-159.65M
-85.46%-132.14M
-274.01%-168.96M
-717.76%-136.21M
28.43%-100.40M
38.76%-71.25M
45.63%-45.17M
79.09%-16.66M
-11.35%-140.28M
-39.94%-116.34M
-109.58%-83.08M
-257.62%-79.67M
-250.38%-125.98M
Cash Flow Statement
Net operating income
-33.34%-24.93M
41.70%-22.73M
54.17%-11.83M
69.88%-5.86M
51.43%-18.70M
10.84%-38.98M
-38.88%-25.81M
34.12%-19.45M
-49.81%-38.50M
-131.23%-43.73M
30.76%-18.59M
-4.09%-29.53M
26.88%-25.70M
68.06%-18.91M
-205.37%-26.84M
-18.43%-28.37M
36.96%-35.14M
-11.93%-59.20M
183.20%25.48M
45.94%-23.95M
Net investment
-154.89%-10.04M
-79.07%3.20M
-66.21%5.00M
-35.71%4.80M
-64.33%18.29M
-30.32%15.29M
-44.88%14.80M
197.25%7.47M
142.14%51.26M
167.74%21.94M
141.11%26.84M
-165.84%-7.69M
157.85%21.17M
-130.77%-32.39M
-312.21%-65.30M
-45.52%11.67M
-178.77%-36.60M
-132.50%-14.04M
-1.95%30.77M
-0.02%21.43M
Net financing
-352.25%-898.00K
--49.80M
4266.47%29.69M
--0.00
-99.13%356.00K
----
157.58%680.00K
--0.00
4663.49%40.97M
----
-99.83%264.00K
-100.00%0.00
-34.50%860.00K
-100.00%0.00
17293.19%155.84M
36143.75%5.80M
-97.88%1.31M
188.34%30.78M
-77.42%896.00K
-98.71%16.00K

FAQs

What is the total revenue of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its total revenue reached 146.07M, with a year-on-year change of 145.24M.

What are the current assets of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its current assets were 103.15M, with a year-on-year change of -34.09.

What are the total assets of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its total assets of Karyopharm Therapeutics Inc were 108.42M, with a year-on-year change of -34.06.

What are the total liabilities of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its total liabilities of Karyopharm Therapeutics Inc were 401.34M, with a year-on-year change of 14.53.

What is the total equity of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its total equity of Karyopharm Therapeutics Inc was -292.93M, with a year-on-year change of -57.47.

What is the net operating income of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its net operating income of Karyopharm Therapeutics Inc was -90.71M, with a year-on-year change of 24.06.

What is the net investment of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its net investment of Karyopharm Therapeutics Inc was 43.38M, with a year-on-year change of -54.57.

What is the net financing of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its net financing of Karyopharm Therapeutics Inc was 30.05M, with a year-on-year change of -27.85.

What is the Earnings Per Share (EPS) of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -17.93, with a year-on-year change of -90.58.

What is the net income of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its net income was -196.04M, with a year-on-year change of -156.52.

What is the net margin of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its net profit margin was -134.21, with a year-on-year change of -155.06.

What is the gross margin of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its gross margin was 95.93, with a year-on-year change of 0.07.

What is the debt-to-asset ratio of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its debt-to-asset ratio was 276.00, with a year-on-year change of 73.95.

What is the Return on Assets (ROA) of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its Return on Assets (ROA) was -143.71, with a year-on-year change of -280.65.

What is the operating profit of Karyopharm Therapeutics Inc?

According to Karyopharm Therapeutics Inc's FY2025 earnings report, its operating profit was -90.71M, with a year-on-year change of 24.06.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy